Navigation Links
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
Date:8/19/2013

ed merger transaction with Immune Pharmaceuticals; the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for AmiKet™ or crolibulin™ will not be successful; the risk that AmiKet™, Azixa® or crolibulin™ will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet™ on attractive terms, a timely basis or at all; the risk that Ceplene® will not receive regulatory approval or marketing authorization in the United States or Canada; the risk that Ceplene® will not achieve significant commercial success; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securit
'/>"/>
SOURCE EpiCept Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EpiCept Reports Second Quarter 2013 Operating and Financial Results
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... PA (PRWEB) May 21, 2015 ... has joined the firm as senior statistician and Principal, ... years of experience in the management and analysis of ... pharmaceutical and chemical industries. , “We’re delighted to have ... capabilities in data analytics,” said Dr. Philippe Cini, Group ...
(Date:5/20/2015)... 20, 2015  Select Medical Corporation ("Select") (NYSE: ... Commission granted early termination of the waiting period ... 1976, as amended, applicable to the acquisition of ... joint venture that Select has created with Welsh, ... previously announced, MJ Acquisition Corporation has signed a ...
(Date:5/20/2015)... Mass. , May 20, 2015  Haemonetics Corporation ... Concannon , President & CEO, will present at The ... York on June 1 st , 2015 ... may access Mr. Concannon,s presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 ... transporter assay services for Drug-Drug Interactions (DDI), Metabolism ... Pharma, a world leader in assessing impact of ... Systems Pharmacology supported by biosimulation, announced today that ... agreement allows both companies to expand their product ...
Breaking Biology Technology:Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3
... , EXTON, Pa., Sept. 8 For ... been ranked as one of the fastest-growing, privately-held companies in the ... Wharton Small Business Development Center, the Entrepreneurs, Forum of Greater Philadelphia, ... Over the past five years, BioTrends has become an established ...
... YORK, Sept. 8 The Alzheimer,s Drug Discovery Foundation ... from the biotechnology industry and academia worldwide to apply for ... Dementia Biomarker Research Award . The goal of the ... aid in early diagnosis, detection and disease monitoring of Lewy ...
... NEW YORK, Sept. 8 Reportlinker.com announces that a ... , Nanoporous Materials , ... , This report analyzes the Global Market for ... for Nanoporous (Microporous) Materials by the following product segments: Zeolites, Activated ...
Cached Biology Technology:BioTrends Research Group is Recognized by the Philly 100 for the Second Consecutive Year 2Alzheimer's Drug Discovery Foundation and the Lewy Body Dementia Association Invite Scientists to Apply for LBD Grant Award Program 2Reportlinker Adds Nanoporous Materials Report 2Reportlinker Adds Nanoporous Materials Report 3Reportlinker Adds Nanoporous Materials Report 4Reportlinker Adds Nanoporous Materials Report 5Reportlinker Adds Nanoporous Materials Report 6
(Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/19/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... advances across the spectrum of science, technology, engineering ... through engaging table-top exhibits at the Coalition for ... Reception. The exhibition/reception will be held from 5:30 ... Rooms B338-340 of the Rayburn House Office Building ...
... old excuse, "I am only overweight because of my ... more evidence that the way our bodies digest and ... for every person. The budding discipline of metabolomics strives ... scientists and food chemists at the Technische Universitaet Muenchen ...
... As published today in Science , researchers from ... of plasticity in how transcription factors, the proteins that ... maintain their function over large evolutionary distances. The ... genes that they regulate by binding to short, sequence-specific ...
Cached Biology News:Science returns to Capitol Hill spotlight at April 14 exhibition 2Science returns to Capitol Hill spotlight at April 14 exhibition 3Science returns to Capitol Hill spotlight at April 14 exhibition 4Metabolic fingerprints offer fresh clues and a new path toward personalized medicine 2Metabolic fingerprints offer fresh clues and a new path toward personalized medicine 3Rewiring of gene regulation across 300 million years of evolution 2
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Goat anti-mouse gamma chain-HRP...
... ( Abpromise for all tested ... Synthetic peptide derived from residues 231 ... (Note: the amino acid sequence is ... Entrez Gene ID: 80829 ...
Phospho-C/EBPbeta (Thr235) Antibody...
Biology Products: